Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 18, 2022 07:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a...
August 11, 2022 16:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 18th

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
August 09, 2022 16:23 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Closing of $16.8 Million Public Offering

ASHBURN, Va., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
August 05, 2022 09:28 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Pricing of $16.8 Million Upsized Public Offering

ASHBURN, Va., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
July 28, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Receipt of Constructive Scientific Advice from EMA for QRX003 Development in Europe

ASHBURN, Va., July 28, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
July 15, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals and Endo Ventures Limited Enter Into Exclusive Distribution and Supply Agreements

ASHBURN, Va., July 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Inc. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has...
July 06, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Opening of First Clinical Site for Netherton Syndrome Clinical Study

ASHBURN, Va., July 06, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases,...
June 15, 2022 16:01 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
June 15, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Licensing and Distribution Agreement with Leading Rare Disease Company for Greater China

ASHBURN, Va., June 15, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...
May 23, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Enters Exclusive Research Agreement for Scleroderma Treatment with Australian University

ASHBURN, Va., May 23, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today...